SCHEMBL4383722

SCHEMBL4383722

CC(C)(O)CN1CCN(C(=O)CCC(=O)c2ccc(Cl)cc2)CC1

nearest known ligand 0.65

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 16/20 0.65
POLB P06746 1/20 0.56
HTT P42858 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
DRD2 P14416 1/20 0.50
DRD4 P21917 1/20 0.50
DRD3 P35462 1/20 0.50
ALDH1A1 P00352 1/20 0.50
LMNA P02545 1/20 0.50
MAPT P10636 1/20 0.50
HPGD P15428 1/20 0.50
TSHR P16473 1/20 0.50
KMT2A Q03164 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4375777 0.99 HRH3 (0.67) HRH3POLBHTTSMN1; SMN2DRD2
SCHEMBL4379338 0.87 HRH3 (0.77) HRH3POLBALDH1A1MAPTKMT2A
SCHEMBL4377725 0.80 HRH3 (0.97) HRH3POLBHTTSMN1; SMN2DRD2
SCHEMBL4377277 0.79 HRH3 (0.98) HRH3POLBHTTSMN1; SMN2DRD2
Hydrochloric Acid SCHEMBL4378983 0.79 HRH3 (1.00) HRH3POLBDRD2DRD4DRD3
SCHEMBL4377369 0.78 HRH3 (0.97) HRH3POLBHTTSMN1; SMN2DRD2
SCHEMBL4377304 0.78 HRH3 (0.97) HRH3POLB
Hydrochloric Acid SCHEMBL4377307 0.78 HRH3 (1.00) HRH3POLBHTTSMN1; SMN2DRD2
SCHEMBL4379382 0.77 HRH3 (0.97) HRH3POLB
Hydrochloric Acid SCHEMBL4379186 0.77 HRH3 (1.00) HRH3POLBHTTSMN1; SMN2DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP claimed
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP disclosed
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113968-A1 Substituted piperazines and diazepanes HRH3, HRH4, HRH1 HRH3 1/4885POLB 3551/4885HTT 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.